FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387206947> ?p ?o ?g. }

• W4387206947 endingPage "e446" @default.
• W4387206947 startingPage "e445" @default.
• W4387206947 abstract "There has been emerging interest in the role of ultra-hypofractionated radiotherapy for high-risk prostate cancer, especially given its low α/β ratio. However, there is limited data on the long-term outcomes of this treatment strategy. The FASTR and FASTR-2 clinical trials were designed to assess the tolerability of stereotactic ablative body radiotherapy (SABR) in high-risk prostate cancer. FASTR was discontinued early due to unacceptable acute toxicity, whereas the acute toxicities in FASTR-2 were minimal. Herein, the long-term results from these trials are reported.Eligible patients had at least 1 high-risk feature as per the National Comprehensive Cancer Network criteria for high-risk prostate cancer, no evidence of metastatic disease, and either a score of 3+ on the Vulnerable Elderly Scale or declined standard therapy. A total of 19 patients from a single institution were enrolled on FASTR between 2011 and 2015. They received 40 Gy to the prostate and 25 Gy to the pelvic lymph nodes in 5 fractions delivered once weekly for 5 weeks, along with 1 year of androgen deprivation therapy (ADT). The excessive acute toxicity in FASTR prompted several modifications in FASTR-2, including the omission of nodal irradiation. A total of 30 patients from the same institution were enrolled on FASTR-2 between 2015 and 2017. They received 35 Gy to the prostate alone in 5 fractions delivered once weekly for 5 weeks, along with 18 months of ADT.A total of 44 patients were eligible for analysis, 16 from FASTR and 28 from FASTR-2. Most patients were >70 years old (77%). High-risk features included Gleason score ≥8 (46%), T3-T4 disease (27%) and baseline PSA >20 (50%). With a median follow-up of 6.4 years, the cumulative incidence of grade ≥3 genitourinary/gastrointestinal toxicity was 50% among FASTR patients and 7% among FASTR-2 patients. At 5 years, the combined rates of biochemical failure-free survival, freedom from distant metastases, prostate cancer-specific survival and overall survival were 72%, 90%, 92% and 83%, respectively. A total of 12 patients (27%) required further treatment. No significant differences in clinical outcomes were noted between the FASTR and FASTR-2 cohorts.SABR for high-risk prostate cancer is an attractive option for reducing treatment burden. Clinical outcomes and toxicity with the FASTR-2 protocol were comparable to conventionally-fractionated radiotherapy plus ADT. Larger prospective, randomized trials exploring the role of SABR with ADT in high-risk disease are necessary to better understand the efficacy and tolerability of this approach." @default.
• W4387206947 created "2023-09-30" @default.
• W4387206947 creator A5013579372 @default.
• W4387206947 creator A5019768466 @default.
• W4387206947 creator A5032441898 @default.
• W4387206947 date "2023-10-01" @default.
• W4387206947 modified "2023-10-17" @default.
• W4387206947 title "Long-Term Outcomes Following Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy in High-Risk Prostate Cancer: Update from the FASTR/FASTR-2 Trials" @default.
• W4387206947 doi "https://doi.org/10.1016/j.ijrobp.2023.06.1626" @default.
• W4387206947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785439" @default.
• W4387206947 hasPublicationYear "2023" @default.
• W4387206947 type Work @default.
• W4387206947 citedByCount "0" @default.
• W4387206947 crossrefType "journal-article" @default.
• W4387206947 hasAuthorship W4387206947A5013579372 @default.
• W4387206947 hasAuthorship W4387206947A5019768466 @default.
• W4387206947 hasAuthorship W4387206947A5032441898 @default.
• W4387206947 hasConcept C106159729 @default.
• W4387206947 hasConcept C121608353 @default.
• W4387206947 hasConcept C126322002 @default.
• W4387206947 hasConcept C126894567 @default.
• W4387206947 hasConcept C143998085 @default.
• W4387206947 hasConcept C162324750 @default.
• W4387206947 hasConcept C187625094 @default.
• W4387206947 hasConcept C197934379 @default.
• W4387206947 hasConcept C2776235491 @default.
• W4387206947 hasConcept C2777899217 @default.
• W4387206947 hasConcept C2778375690 @default.
• W4387206947 hasConcept C2780192828 @default.
• W4387206947 hasConcept C509974204 @default.
• W4387206947 hasConcept C71924100 @default.
• W4387206947 hasConcept C85393063 @default.
• W4387206947 hasConcept C91602232 @default.
• W4387206947 hasConceptScore W4387206947C106159729 @default.
• W4387206947 hasConceptScore W4387206947C121608353 @default.
• W4387206947 hasConceptScore W4387206947C126322002 @default.
• W4387206947 hasConceptScore W4387206947C126894567 @default.
• W4387206947 hasConceptScore W4387206947C143998085 @default.
• W4387206947 hasConceptScore W4387206947C162324750 @default.
• W4387206947 hasConceptScore W4387206947C187625094 @default.
• W4387206947 hasConceptScore W4387206947C197934379 @default.
• W4387206947 hasConceptScore W4387206947C2776235491 @default.
• W4387206947 hasConceptScore W4387206947C2777899217 @default.
• W4387206947 hasConceptScore W4387206947C2778375690 @default.
• W4387206947 hasConceptScore W4387206947C2780192828 @default.
• W4387206947 hasConceptScore W4387206947C509974204 @default.
• W4387206947 hasConceptScore W4387206947C71924100 @default.
• W4387206947 hasConceptScore W4387206947C85393063 @default.
• W4387206947 hasConceptScore W4387206947C91602232 @default.
• W4387206947 hasIssue "2" @default.
• W4387206947 hasLocation W43872069471 @default.
• W4387206947 hasLocation W43872069472 @default.
• W4387206947 hasOpenAccess W4387206947 @default.
• W4387206947 hasPrimaryLocation W43872069471 @default.
• W4387206947 hasRelatedWork W1980245127 @default.
• W4387206947 hasRelatedWork W2030798726 @default.
• W4387206947 hasRelatedWork W2127440557 @default.
• W4387206947 hasRelatedWork W2761687716 @default.
• W4387206947 hasRelatedWork W3021633275 @default.
• W4387206947 hasRelatedWork W4220991042 @default.
• W4387206947 hasRelatedWork W4221041809 @default.
• W4387206947 hasRelatedWork W4251402126 @default.
• W4387206947 hasRelatedWork W4319748405 @default.
• W4387206947 hasRelatedWork W95247034 @default.
• W4387206947 hasVolume "117" @default.
• W4387206947 isParatext "false" @default.
• W4387206947 isRetracted "false" @default.
• W4387206947 workType "article" @default.